Tempus AI, Inc. (TEM)

Tempus reported Q3 revenue of $411.5 million, up 23% year over year, and raised 2026 revenue guidance to $1.60–$1.605 billion. Growth centers on oncology testing, pharmaceutical data partnerships, and the planned Personalis acquisition, while reimbursement timing, ongoing losses, and valuation remain key investor concerns. TEM fell 5.04% on November 10, including regular-session and after-hours trading.